Effects of third-generation aromatase inhibitors on bone
- 31 May 2006
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 42 (8) , 1044-1051
- https://doi.org/10.1016/j.ejca.2005.10.028
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast CancerNew England Journal of Medicine, 2003
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancerCancer, 2003
- Osteoclast differentiation and activationNature, 2003
- The development and function of the skeleton and bone metastasesCancer, 2003
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- Fast and Slow Bone LosersDrugs & Aging, 1998
- Aromatase inhibitors in the treatment of breast cancerThe Journal of Steroid Biochemistry and Molecular Biology, 1994
- Effects of Adjuvant Tamoxifen and of Cytotoxic Therapy on Mortality in Early Breast CancerNew England Journal of Medicine, 1988
- Aromatase inhibitors: Basic and clinical studiesJournal of Steroid Biochemistry, 1987